Vicore Pharma Holding AB (publ)
VICO
Rank in Stocks
#14650
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company,... Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
Share Price
$1.10
Last synced: 2026-11-09
Market Cap
$310.91M
Change (1 day)
6.84%
Change (1 year)
2.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vicore Pharma Holding AB (publ) (VICO)
Category
Healthcare
EPS for Vicore Pharma Holding AB (publ) (VICO)
EPS as of June 2026 TTM: $-0.19
According to Vicore Pharma Holding AB (publ)'s latest financial reports, its current EPS (TTM) is $-0.19. At the end of 2025 the company had an EPS of $-0.22, a decrease compared to its 2024 EPS of $-0.07.
EPS history for Vicore Pharma Holding AB (publ) from 2012 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.19 | -11.91% |
| 2025 | $-0.22 | 217.21% |
| 2024 | $-0.07 | -78.70% |
| 2023 | $-0.32 | -16.57% |
| 2022 | $-0.38 | -18.53% |
| 2021 | $-0.47 | 43.21% |
| 2020 | $-0.33 | 41.70% |
| 2019 | $-0.23 | 117.69% |
| 2018 | $-0.11 | 14.42% |
| 2017 | $-0.09 | 79.69% |
| 2016 | $-0.05 | 36.41% |
| 2015 | $-0.04 | -127.91% |
| 2014 | $0.14 | -830.11% |
| 2013 | $-0.02 | 30.99% |
| 2012 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -8,180.50% |
US
|
|
| $-7.07 | 3,548.09% |
US
|
|
| $-5.29 | 2,629.62% |
AU
|
|
| $12.88 | -6,746.08% |
BE
|
|
| $21.56 | -11,224.87% |
NL
|
Questions about Vicore Pharma Holding AB (publ)'s earnings per share (EPS)
What is Vicore Pharma Holding AB (publ)'s earnings per share (EPS)?
Vicore Pharma Holding AB (publ)'s earnings per share (EPS) over the last twelve months is $-0.19, as of Jun 2026.
What was Vicore Pharma Holding AB (publ)'s earnings per share (EPS) in 2025?
In 2025, Vicore Pharma Holding AB (publ)'s earnings per share (EPS) was $-0.22, compared with $-0.07 in 2024.
How has Vicore Pharma Holding AB (publ)'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vicore Pharma Holding AB (publ)'s earnings per share (EPS) was highest in 2024 ($-0.07) and lowest in 2021 ($-0.47).
How does Vicore Pharma Holding AB (publ)'s earnings per share (EPS) compare with similar companies?
Vicore Pharma Holding AB (publ)'s earnings per share (EPS) ($-0.19) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.